Details for Patent: RE46604
✉ Email this page to a colleague
Title: | Treatment of circadian rhythm disorders |
Abstract: | Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
Inventor(s): | Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
Assignee: | VANDA PHARMACEUTICALS, INC. (Washington, DC) |
Filing Date: | Feb 24, 2016 |
Application Number: | 15/051,978 |
Claims: | 1. A method of entraining a patient suffering from Non-24 to a 24 hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, and maintaining said 24 hour sleep-wake cycle said method comprising: treating the patient by orally administering to the patient 20 mg of tasimelteon once daily before a target bedtime. 2. The method of claim 1 wherein the patient is totally blind. 3. The method of claim 2 wherein the tasimelteon is administered 0.5 to 1.5 hours before the target bedtime. 4. The method of claim 3 wherein treatment is initiated on a day in which the patient's urinary aMT6s acrophase is predicted to be within about 5.5 hours before target wake time and about 2.5 hours after target wake time. .[.5. The method of claim 3 wherein treatment is initiated on a day in which the patient's urinary cortisol acrophase is predicted to be within about 5.5 hours before target wake time and about 2.5 hours after target wake time..]. .Iadd.6. The method of claim 1 further comprising: (i) first determining if the patient is also being treated with a CYP1A2 inhibitor, and (ii) if the patient is being treated with a CYP1A2 inhibitor, reducing the dose of the CYP1A2 inhibitor..Iaddend. .Iadd.7. The method of claim 6 wherein the CYP1A2 inhibitor is ciprofloxacin, fluvoxamine, or verapamil..Iaddend. .Iadd.8. The method of claim 7 wherein the CYP1A2 inhibitor is fluvoxamine..Iaddend. |